Vaccines are the most effective way to prevent infectious diseases in the human population and polysaccharide-protein conjugate vaccines, developed for increased immunogenicity, are considered the safest and most successful vaccine product developed in the last 30 years. These novel, complex moieties require robust analytical techniques to fully monitor their structural identity, quantity and conformity.
Detailed characterisation of such novel products continuously evolves, creating demand for new, powerful technologies to provide accurate measurements at the molecular level for all aspects of conjugate vaccines that require identification, as well as quantification of polysaccharide content. Furthermore it is critical to quantify such qualities throughout the manufacturing chain in the pharmaceutical industry to ensure the production of safe and effective vaccines.
Nuclear magnetic resonance (NMR) spectroscopy has emerged as one of the best, new broad spectrum technological solutions to compliment the biological assays used to test the efficacy of material being processed. The information from various techniques, currently used for chemical characterisation of bulk material through the manufacturing process to its final product state, can be substituted or complimented by 1D 1H NMR spectroscopy, thereby significantly increasing the level of quality control (QC) on processing and reducing time through the process. The advantages provided by process monitoring with 1D 1H NMR spectroscopy will increase throughput and confidence in the production of conjugate vaccines helping to speed their release to market.
Wednesday, June 22, 2022
11:00 AM EDT / 5:00 PM CEST
Dr. Francesco Berti
Scientific Director, Technical R&D GSK Vaccines
Application Scientist, Bruker